三星生物公司以2.8亿美元收购GSK的马里兰制药厂, Samsung Biologics to buy GSK’s Maryland drug plant for $280M, its first U.S. site.

Samsung Biologics同意收购马里兰州的GlaxoSmithKline Rockville, 毒品生产设施为2.8亿美元, Samsung Biologics has agreed to acquire GlaxoSmithKline’s Rockville, Maryland, drug production facility for $280 million, marking its first U.S. manufacturing site. 该设施原为人类基因组科学,拥有60 000升药物物质能力,并将予以扩大和更新。 The facility, formerly Human Genome Sciences, has 60,000 liters of drug substance capacity and will be expanded and upgraded. 这笔交易预计将在2026年Q1结束时结束,其中包括500多名雇员,加强了三星在美国的生物制药供应链。 The deal, expected to close by end of Q1 2026, includes over 500 employees and strengthens Samsung’s U.S. biopharmaceutical supply chain.